S0000B: Vitamin E and/or Selenium in Preventing Cataract and Age-Related Macular Degeneration in Men on SELECT SWOG-S0000

• Status: Completed
• Trial end date: 2018-05-01
• Target enrollment: 0
• Participant gender: Male

Summary

RATIONALE: Aging may affect a person's vision. Vitamin E and/or selenium may help prevent cataracts or age-related macular degeneration in men receiving these drugs as part of a clinical trial for the prevention of prostate cancer.

PURPOSE: This clinical trial is studying vitamin E and/or selenium to see how well they work in preventing cataract and age-related macular degeneration in men enrolled on SELECT (SWOG-S0000).

• Phase: Phase 3
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Southwest Oncology Group
• Collaborators: National Cancer Institute (NCI); National Eye Institute (NEI)
• Treatments: alpha-Tocopherol; Selenium; Tocopherols; Tocotrienols; Vitamin E; Vitamins

Criteria

DISEASE CHARACTERISTICS:

• Enrolled on the Selenium and Vitamin E Prostate Cancer Prevention Trial (SELECT) SWOG-S0000

• Diagnosis of 1 of the following:

• Age-related macular degeneration (AMD) at baseline or at follow-up

• Cataract or a cataract extraction at follow-up (Closed for accrual as of 10/01/29)

• Participants with a prior diagnosis of cataract at baseline followed by another cataract event (cataract diagnosis or a cataract extraction) at follow-up are not eligible

• Participants with a prior diagnosis of cataract at baseline followed by a diagnosis of AMD at follow-up are eligible

PATIENT CHARACTERISTICS:

• See Disease Characteristics

PRIOR CONCURRENT THERAPY:

• Not applicable